Two Sigma Advisers

Two Sigma Advisers’s enGene Therapeutics ENGN Stock Holding History

Two Sigma Advisers’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,300	Closed	-$156K	–	677
2025 Q4	$156K	Buy	+17,300	New	+$139K	﹤0.01%	2161

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Two Sigma Advisers's ENGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 17,300 shares — an estimated $156K sold.

Two Sigma Advisers first reported a position in ENGN in Q4 2025 and held it in 1 quarter. The position peaked at $156K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

Two Sigma Advisers reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 17,300 enGene Therapeutics shares in Q1 2026, an estimated $156K.
Two Sigma Advisers first reported a position in enGene Therapeutics in Q4 2025 and held it in 1 quarter.
Two Sigma Advisers's enGene Therapeutics position peaked at $156K in Q4 2025.
61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.